Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28442
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHawkes, Eliza A-
dc.contributor.authorBarraclough, Allison-
dc.contributor.authorSehn, Laurie H-
dc.date2021-
dc.date.accessioned2022-01-10T03:24:33Z-
dc.date.available2022-01-10T03:24:33Z-
dc.date.issued2022-02-10-
dc.identifier.citationBlood 2022; 139(6): 822-834en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28442-
dc.description.abstractDLBCL, the most common lymphoma subtype, is localized in 25-30% of patients. Prognosis in patients with limited-stage DLBCL (LS-DLBCL) is excellent with 10-year overall survival of at least 70-80%. Improved insights into the disease biology, the availability of positron-emission tomography (PET) scans and recent dedicated clinical trials within this unique population, have led to evolving treatment paradigms. However, no standard definition of LS-DLBCL exists, and while generally defined as Ann Arbor stages I-II disease with largest mass size <10cm in diameter, variations across studies cause challenges in interpretation. Similar to advanced-stage disease, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) immunochemotherapy forms the basis of treatment, with combined modality therapy including 3 cycles of systemic treatment and involved-site radiation therapy being a predominant historical standard. Yet the well-described continuous risk of relapse beyond 5 years and established late complications of radiotherapy have challenged previous strategies. More rigorous baseline staging and response assessment with PET may improve decision making. Recent clinical studies have focused on minimizing toxicities while maximizing disease outcomes using strategies such as abbreviated immunochemotherapy alone and PET-adapted radiotherapy delivery. This comprehensive review provides an update of recent literature with recommendations for integration into clinical practice for LS-DLBCL patients.en
dc.language.isoeng-
dc.titleLimited-stage Diffuse Large B-cell Lymphoma.en
dc.typeJournal Articleen
dc.identifier.journaltitleBlooden
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationBC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canadaen
dc.identifier.affiliationSchool of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australiaen
dc.identifier.affiliationEastern Health, Melbourne, VIC, Australiaen
dc.identifier.affiliationFiona Stanley Hospital, Perth, WA, Australiaen
dc.identifier.affiliationThe University of British Columbia, Vancouver, BC, Canadaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34932795/en
dc.identifier.doi10.1182/blood.2021013998en
dc.type.contentTexten
dc.identifier.orcid0000-0002-0376-2559en
dc.identifier.orcid0000-0003-1615-0540en
dc.identifier.pubmedid34932795-
local.name.researcherBarraclough, Allison
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptClinical Haematology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.